Evaluating inflammatory markers in sepsis patients
Role of Inflammatory Markers Measured Using Flow Cytometry in the Diagnosis and Prognosis of Sepsis in Surgical Cancer Patients
This study is testing if certain inflammatory markers in the blood can help doctors better diagnose and predict outcomes for cancer patients with sepsis after surgery.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 60 (estimated) |
| Ages | 18 Years to 65 Years |
| Sex | All |
| Sponsor | National Cancer Institute, Egypt Academic / other |
| Locations | 1 site (Cairo) |
| Trial ID | NCT06111963 on ClinicalTrials.gov |
What this trial studies
This observational study aims to assess the expression of CD64 in activated neutrophils and CD64 and IL17A regulatory T cells in patients diagnosed with sepsis, particularly those who are cancer patients admitted to the surgical ICU after cancer-related surgeries. The primary objective is to evaluate these markers as potential diagnostic and prognostic indicators for sepsis. The study will utilize serology tests to gather relevant data on these inflammatory markers. By understanding the role of these markers, the study seeks to improve the management of sepsis in this vulnerable patient population.
Who should consider this trial
Good fit: Ideal candidates for this study are cancer patients who have undergone surgery and are diagnosed with sepsis.
Not a fit: Patients who refuse to participate or have significant intraoperative complications or impaired kidney or liver function may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved diagnostic and prognostic tools for managing sepsis in cancer patients.
How similar studies have performed: While this approach is focused on specific inflammatory markers in a unique patient population, similar studies have shown promise in using biomarkers for diagnosing and prognosing sepsis.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Cancer patients admitted to the surgical ICU following cancer related surgeries and diagnosed with sepsis Exclusion Criteria: * Refusal of patient or patient guardian to participate. * Intraoperative massive blood loss and massive blood transfusion * Patients with impaired preoperative kidney or liver function tests
Where this trial is running
Cairo
- Walaa Y Elsabeeny — Cairo, Egypt (Recruiting)
Study contacts
- Principal investigator: Walaa Y Elsabeeny, MD — National Cancer Institute, Cairo University
- Study coordinator: Walaa Y Elsabeeny, MD
- Email: walaa.elsabeeny@nci.cu.edu.eg
- Phone: +201007798466
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.